Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467934 · ClinicalTrials.gov registry record
FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging
A clinical trial of Fever, sponsored by Columbia University.
- Completed
- Registry status
- 530
- Enrollment target
- 2
- Study locations
NCT01467934 is a study of Fever that has completed, run by Columbia University. The registered enrollment target is 530 participants, roughly in line with the 570-participant average among 18 other Fever trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT01467934, a study of Fever, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 530 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, the investigators will prospectively assess fever rates and other associated vaccine adverse events in 6-23 month old patients during days 0-7 after administration of trivalent inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) concomitantly compared to those who receive trivalent inactivated influenza vaccine (TIV) or 13-valent pneumococcal conjugate vaccine (PCV13) administered non-concomitantly. The investigators hypothesize that fever rates will be significantly higher during the 0-1 days after vaccination when inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) are given concomitantly than when TIV or PCV13 is administered non-concomitantly.
Conditions Studied
Study Locations (2)
Georgia
- Centers for Disease Control and Prevention - Atlanta
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467934
The ClinicalTrials.gov registry entry for NCT01467934 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 570-participant average among 18 other Fever trials with a reported enrollment target. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fever appearing as the primary indexed condition, and to 0 interventions.
NCT01467934 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT01467934 about?
NCT01467934 is a clinical study titled "FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging". In this study, the investigators will prospectively assess fever rates and other associated vaccine adverse events in 6-23 month old patients during days 0-7 after administration of trivalent inactivated influenza vaccine (TIV) and 13-valent pneumococcal conjugate vaccine (PCV13) concomitantly compa...
What is the current status of trial NCT01467934?
This trial is currently completed. The enrollment target is 530 participants. The study started on 2011-11. Estimated completion is 2012-06.
What conditions does trial NCT01467934 study?
This clinical trial studies the following conditions: Fever.
Who is sponsoring clinical trial NCT01467934?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01467934 being conducted?
This trial has 2 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
RECRUITING · NA
-
Remote Temperature Monitoring of Patients At Risk for Developing Fever
RECRUITING · NA
-
Prescription Antipyretics to Decrease Unscheduled Return Visits In A Pediatric Emergency Department
RECRUITING · NA
-
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
RECRUITING
-
Safety of RSV Preventive Monoclonal Antibody
RECRUITING · Phase 4
-
Tympanic Thermometer Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.